BioAtla, Inc. Profile Avatar - Palmy Investing

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…

Biotechnology
US, San Diego [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

BioAtla, Inc. has no acquisition track records yet.

M&A Deals · History

BioAtla, Inc. has no acquisition track records yet.

End of BCAB's Analysis
CIK: 1826892 CUSIP: 09077B104 ISIN: US09077B1044 LEI: - UEI: -
Secondary Listings
BCAB has no secondary listings inside our databases.